Retatrutide Breaks 30%: ADA 2026 Obesity Pipeline | Denver
Research Brief | Dr. Ethan Lazarus, MD | Clinical Nutrition Center | July 13, 2026
The ADA Scientific Sessions in New Orleans just wrapped, and if you’ve been watching the obesity medicine pipeline, this year’s data should get your attention. Three major readouts dropped — and for the first time in a while, the field is shifting in ways that actually matter.
Retatrutide: 30% and Counting
Let’s start with the headline. Eli Lilly’s retatrutide — a triple agonist targeting GLP-1, GIP, and glucagon — posted primary 80-week results from TRIUMPH-1 showing 20% body weight reduction. That’s significant on its own. But the extension data is what made people in the room lean forward: participants who continued to 104 weeks at the highest dose exceeded 30% weight loss. No non-surgical obesity intervention has published results like this. Full peer-reviewed data published simultaneously in the *New England Journal of Medicine*.
In the companion TRANSCEND-T2D trial, retatrutide delivered a 2% A1C reduction in type 2 diabetes — on par with semaglutide and tirzepatide.
Survodutide: First Dual GLP-1/Glucagon Phase 3
From Boehringer Ingelheim: survodutide hit 16.6% weight loss at 76 weeks in SYNCHRONIZE-1. It’s a dual GLP-1/glucagon agonist — the first Phase 3 readout for that mechanism in obesity. The glucagon component appears to drive additional thermogenic and hepatic fat effects. Early signal, but worth watching.
Amylin: A New Backbone
Amylin-based therapies are establishing themselves as a legitimate therapeutic backbone. The GI tolerability profile looks meaningfully better than current GLP-1 monotherapies, with robust weight loss signals. This is an expansion of the toolkit, not a replacement.
The Field Is Shifting
Here’s what strikes me most: the conversation at ADA has moved — at least partially — away from “how much weight can we take off?” toward composite endpoints. Resolution of obstructive sleep apnea. Liver fat reduction. BMI and A1C out of range simultaneously. We’re thinking about what obesity medicine actually resolves in a person’s life.
Colorado Context
Colorado ranks among the lower-obesity states, but Denver-metro is not immune — and prevalence has been climbing. At Clinical Nutrition Center, I work every day with people who have plateaued on current GLP-1 therapies and are asking what’s next. The retatrutide and survodutide data suggest that “next” is not theoretical. It’s arriving.